The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Syndax Pharmaceuticals Pretax Margin % Related Terms
Syndax Pharmaceuticals Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Syndax Pharmaceuticals's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1T3 vs IOVA, GLUE, TYRA: Pretax Margin % Comparison
For the Biotechnology subindustry, Syndax Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syndax Pharmaceuticals Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Syndax Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syndax Pharmaceuticals (FRA:1T3) has a Pretax Margin % of -65.79% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Syndax Pharmaceuticals and its competitors. According to the industry distribution chart, Syndax Pharmaceuticals ranks #490 out of 941 companies in the Biotechnology industry, placing it in the top 52.1%.
Is Syndax Pharmaceuticals' Pretax Margin % too high?
Syndax Pharmaceuticals' current Pretax Margin % is -65.79%. Based on the distribution chart, Syndax Pharmaceuticals ranks #490 out of 941 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Syndax Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Pretax Margin % compare to IOVA and GLUE?
According to the Biotechnology industry distribution chart, Syndax Pharmaceuticals ranks #490 out of 941 companies for Pretax Margin %. This places Syndax Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Syndax Pharmaceuticals and its competitors. Syndax Pharmaceuticals's current Pretax Margin % is -65.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (FRA:1T3) has a current Pretax Margin % of -65.79%. The current Pretax Margin % is -65.79%. Syndax Pharmaceuticals' overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current Pretax Margin % is -65.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
25GF Score
Get the complete analysis for FRA:1T3
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1T3 has been successfully added to your 
